New drugs targeting calcitonin gene-related peptide for the management of migraines
Expert Opin Emerg Drugs. 2023 Nov 23. doi: 10.1080/14728214.2023.2288334. Online ahead of print.ABSTRACTINTRODUCTION: Significant advances in migraine research have contributed to the development of new drugs for the treatment of migraine. Monoclonal antibodies (mAbs) against Calcitonin Gene-Related Peptide (CGRP) or its receptor and CGRP receptor antagonists (gepants) have been associated with a good safety profile and resulted in an overall efficacy in reducing the number of monthly migraine days both in episodic and chronic forms of migraine.AREAS COVERED: The results from main investigation studies (phase 2 or 3) of CG...
Source: Expert Opinion on Emerging Drugs - November 23, 2023 Category: Drugs & Pharmacology Authors: Claudio Tana Francesco Cipollone Maria Adele Giamberardino Paolo Martelletti Source Type: research
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond
Expert Opin Emerg Drugs. 2023 Nov 12:1-14. doi: 10.1080/14728214.2023.2281416. Online ahead of print.ABSTRACTINTRODUCTION: Currently approved drug treatments for idiopathic pulmonary fibrosis (IPF), pirfenidone and nintedanib, have been shown to slow lung function decline and improve clinical outcomes. Since significant advances in the understanding of pathogenetic mechanisms in IPF, novel potential agents are being tested to identify new targeted and better tolerated therapeutic strategies.AREAS COVERED: This review describes the evidence from IPF phase II and III clinical trials that have been completed or are ongoing in...
Source: Expert Opinion on Emerging Drugs - November 13, 2023 Category: Drugs & Pharmacology Authors: Carmelo Sofia Alessia Comes Giacomo Sgalla Luca Richeldi Source Type: research
